| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, and Clinical Correlates |
1 Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland;
2 Department of Pathology, Mayo Clinic, Rochester, Minnesota;
3 Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas;
4 Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut; and
5 Department of Surgery, Union Memorial Hospital, Baltimore, Maryland
Purpose: Despite the availability of cellular markers associated with cell cycle, apoptosis, and DNA repair, predictive factors for pathological complete response (CR) and overall survival (OS) are few in patients with locally advanced esophageal cancer. This study evaluates the role of clinical and cellular markers in predicting CR and OS in patients with esophageal cancer.
Experimental Design: Patients were treated with infusional cisplatin and 5-fluorouracil combined with daily radiotherapy followed by esophagectomy. Pretreatment tumors (n = 54) were analyzed for epidermal growth factor receptor (EGF-R), bax, and bcl-2 expression by immunohistochemistry and for p53 mutations by direct DNA sequencing of exons 5–8. Clinical covariates included patients’ age at enrollment; gender; Barrett’s metaplasia; and tumor location, histology, and differentiation. Logistic regression and survival analyses were used to evaluate the predictors.
Results: Age ranged from 32 to 75 years; most patients were male (45 male; 9 female); and tumors were distal (47 distal; 7 mid), adenocarcinoma (41 adenocarcinomas; 13 squamous cell carcinomas), and moderately differentiated (33 moderate; 6 well; 15 poor). Female gender predicted CR (odds ratio 7.5; 95% confidence interval, 1.4–41). The OS was 43% at 5 years. Presence of CR (P < 0.001 log rank) and p53 mutation (P = 0.051 log rank) correlated with increased OS, whereas increased EGF-R expression predicted poor OS (P = 0.009 log rank). EGF-R remained significant when adjusted for clinical covariates. There was a trend toward increased OS related to better tumor differentiation and decreased bcl-2.
Conclusions: These data suggest that EGF-R and p53 mutation may be used as both outcome predictors and targets for molecular therapy for esophageal cancer.
This article has been cited by other articles:
|
|
 |
|
  B. Burtness, M. Gibson, B. Egleston, R. Mehra, L. Thomas, R. Sipples, M. Quintanilla, J. Lacy, S. Watkins, J. R. Murren, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer Ann. Onc., July 1, 2009; 20(7): 1242 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K R Fareed, P Kaye, I N Soomro, M Ilyas, S Martin, S L Parsons, and S Madhusudan Biomarkers of response to therapy in oesophago-gastric cancer Gut, January 1, 2009; 58(1): 127 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ekman, M. Bergqvist, C.-H. Heldin, and J. Lennartsson Activation of Growth Factor Receptors in Esophageal Cancer Implications for Therapy Oncologist, October 1, 2007; 12(10): 1165 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kleinberg and A. A. Forastiere Chemoradiation in the Management of Esophageal Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4110 - 4117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Kang, J. H. Han, K. J. Lee, J.-H. Choi, J. I. Park, H. I. Kim, H.-W. Lee, J. H. Jang, J. S. Park, H. C. Kim, et al. Low Expression of Bax Predicts Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Treated with Definitive Chemoradiotherapy Clin. Cancer Res., July 15, 2007; 13(14): 4146 - 4153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, and A. A. Forastiere Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study J. Clin. Oncol., December 1, 2005; 23(34): 8646 - 8654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. P. Tew, D. P. Kelsen, and D. H. Ilson Targeted Therapies for Esophageal Cancer Oncologist, September 1, 2005; 10(8): 590 - 601. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
